Overcoming the unmet need of Richter transformation: the use of pirtobrutinib
Mené sur 82 patients présentant un syndrome de Richter (âge médian : 67 ans), cet essai multicentrique de phase I/II détermine la dose maximale tolérée du pirtobrutinib (un inhibiteur de la tyrosine kinase de Bruton) en monothérapie puis évalue son efficacité du point de vue du taux de réponse globale
Treatment of chronic lymphocytic leukaemia has transformed in the past decade. Omitting chemotherapy and introducing target therapies has improved progression-free survival and, more importantly, overall survival. Using Bruton tyrosine kinase (BTK) inhibitors and B-cell lymphoma inhibitors sequentially offers a treatment strategy that provides 10-year progression-free survival for almost all patients requiring therapy